| Name | Title | Contact Details |
|---|
Allegheny Technologies Incorporated (ATI) is a global manufacturer of technically advanced specialty materials and complex components. We are a market leader in manufacturing and producing differentiated specialty alloys and forgings that require our unique manufacturing and precision machining capabilities and our innovative new product development competence. ATI produces nickel-based alloys and superalloys, titanium and titanium-based alloys, specialty alloys, stainless steels, zirconium and other related alloys in many mill product forms. Our capabilities range from alloy development, to melting and hot-working, through highly engineered finished components. We are a leader in producing nickel-based alloy and titanium-based alloy powders for use in next-generation jet engine forgings and 3D-printed products. Our key global markets include, aerospace and defense, oil and gas, chemical and hydrocarbon processing, electrical energy, medical, automotive and other industrial markets.
Listen Technologies brings power and clarity to the sounds that enrich people`s lives—with solutions that overcome the challenges of noise, distance, clashing conversations, and hearing loss to deliver precise and personalized audio in any setting or environment.
Vibra Finish, Limited is a Mississauga, ON-based company in the Manufacturing sector.
Khalsa Brain Games is a San Francisco, CA-based company in the Manufacturing sector.
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its flagship product, CytoSorb®, is approved in the European Union, distributed in 75 countries worldwide, and has accumulated more than 212,000 human treatments to date, to reduce "cytokine storm" and other toxins that can cause organ failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, has received two U.S. FDA Breakthrough Device Designations to remove two separate blood thinners during cardiothoracic surgery, including ticagrelor and the direct oral anticoagulants (DOAC) apixaban and rivaroxaban, and is undergoing pivotal clinical studies.